SEQIRUS VACCINES LIMITED
Company Information
- Company Number
- 03970089
- Registered Address
- Gaskill Road, Liverpool, Merseyside, L24 9GR
- Status
- Active
- Employee Count
- 675
- Turnover
- £197,700,000
- EBITDA
- £31,300,000
Additional Details
- Website
- https://novartis.co.uk
- Company Type
- Private limited Company
- Incorporated On
- 11 April 2000
- Nature of Business
- 21100 - Manufacture of basic pharmaceutical products21200 - Manufacture of pharmaceutical preparations
- Industries
- Life Sciences And Medical Technology
- Region
- North West
Time to Pay
Payment Timeline
Payment Features
Payment Score History
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 11 Jul 2025 | 42 | 59% | 31% | 10% | 23% |
| 01 Jul 2024 - 31 Dec 2024 | 31 Jan 2025 | 45 | 53% | 34% | 13% | 32% |
| 01 Jan 2024 - 30 Jun 2024 | 26 Jul 2024 | 53 | 47% | 35% | 18% | 39% |
| 01 Jan 2023 - 30 Jun 2023 | 27 Jul 2023 | 46 | 59% | 31% | 10% | 20% |
| 01 Jul 2022 - 31 Dec 2022 | 20 Jan 2023 | 42 | 57% | 32% | 11% | 18% |
| 01 Jan 2022 - 30 Jun 2022 | 25 Jul 2022 | 47 | 54% | 31% | 15% | 25% |
| 01 Jan 2021 - 30 Jun 2021 | 08 Jul 2021 | 39 | 58% | 34% | 8% | 19% |
| 01 Jul 2020 - 31 Dec 2020 | 18 Jan 2021 | 39 | 57% | 36% | 7% | 23% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
60 days
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
60
Dispute Resolution Process
All queries are addressed via the Seqirus UK Helpdesk (APHelpdesk@Seqirus.com) managed by our business partners, CAP Gemini. Any invoices not quoting a purchase order, or if there are any price/quantity issues are sent back to the supplier with a covering email to resolve with the relevant person in the business. If there are any other ad-hoc queries, these are dealt with via email by the Accounts Payable team.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
SEQIRUS VACCINES LIMITED is a global biopharmaceutical company that specializes in the development and manufacturing of vaccines to prevent infectious diseases. The company is committed to sustainability and has implemented various initiatives to reduce its environmental impact.
Their sustainability program focuses on reducing carbon emissions, waste management, and energy efficiency. They have also implemented sustainable packaging practices and are constantly working towards reducing their water usage.
The company's product portfolio includes vaccines for influenza, meningococcal disease, and rabies. They also offer a range of services such as vaccine development, clinical trials, and regulatory support.
The key people at SEQIRUS VACCINES LIMITED include the CEO, Paul Perreault, and the Executive Vice President, Global Operations, Gordon Naylor. They lead a team of highly skilled professionals who are dedicated to bringing innovative and life-saving vaccines to the market.
The company's registered office address is Parkville, Victoria, Australia. For more information about their products and services, or to get in touch with the company, you can visit their website at www.seqirus.com.
